New Trial Suggests CV Benefit With EPA: RESPECT-EPA

Although the open-label trial has many limitations, it could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose eicosapentaenoic acid.
Medscape Medical News

source https://www.medscape.com/viewarticle/983621?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?